Target intelligence / Profile preview

C-X-C motif chemokine ligand 11 (CXCL11)

Target
CXCL11
Molecular classification
Chemokine, Cytokine, CXC chemokine family, Signaling molecule, Other
01

Overview

C-X-C motif chemokine ligand 11 (CXCL11) is a small inducible cytokine of the CXC chemokine family primarily involved in immune cell chemotaxis, especially attracting activated T cells through its high-affinity interaction with the chemokine receptor CXCR3. It is also a ligand for CXCR7, mediating alternative, nonclassical signaling. CXCL11 is induced by interferons (notably IFN-γ and IFN-β) and plays a major role in regulating lymphocyte movement, inflammation, and angiostasis. Aberrant expression of CXCL11 is associated with inflammation, tumorigenesis, chemoresistance, and prognosis in a broad range of cancers, with context-dependent effects that can either inhibit or support tumor growth depending on cell type, tumor microenvironment, and receptor expression. CXCL11 serves as a potential therapeutic target and biomarker in cancer and cardiovascular diseases, but its diverse roles make direct targeting therapeutically challenging.

Other names
Interferon-inducible T-cell alpha chemoattractant (I-TAC)Interferon-gamma-inducible protein 9 (IP-9)b-R1H174SCYB11SCYB9B
02

Mechanism of action

Drugs that target this pathway generally act to block CXCR3 or CXCR7-mediated chemotaxis or downstream signaling, modulate immune cell migration, or impact the tumor microenvironment

03

Biological functions

Immune responseChemotaxisSignal transductionRegulation of lymphocyte traffickingAngiostasisModulation of tumor progression
04

Disease associations

CancerInflammationCardiovascular diseaseInfectionLiver fibrosisTumorigenesisChemoresistance
05

Safety considerations

Potential for impaired immune response or exacerbated inflammation when altering CXCL11 signalingcomplexity due to dual pro- and anti-tumor roles depending on cancer type and receptor contextdifficulty in selective targeting
06

Interacting drugs

No FDA-approved drugs directly target CXCL11; CXCL11 is part of chemokine signaling targeted by experimental agents and as a biomarker in trials
07

Biomarkers

Biomarker for heart failure progressionleft ventricular dysfunctiontumor progressionprognosis in multiple tumor types

Beyond the preview

Go deeper on C-X-C motif chemokine ligand 11 (CXCL11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-X-C motif chemokine ligand 11 (CXCL11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call